Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.K. Biotech Renovo's Future On The Line As Phase III Lead Crashes

This article was originally published in The Pink Sheet Daily

Executive Summary

The Phase III failure of Renovo's scar reduction treatment threatens the company's future and is the latest in a string of bad news for U.K. biotech.

You may also be interested in...



Reinventing Cell Therapy And Biomaterials

A profound redefinition of the role of many cell types and biomaterials in regenerative medicine is under way as researchers have moved away from the notion that cells introduced into the body will integrate and become functioning tissue.

Cell-Therapy Deals A "Strategic Priority" For Shire

Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.

Cell-Therapy Deals A "Strategic Priority" For Shire

Shire seeks to build on its May 2011 acquisition of Advanced BioHealing with further cell-therapy deals.

Related Content

Topics

UsernamePublicRestriction

Register

PS071840

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel